Lexeo Therapeutics, Inc. (LXEO)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$3.38−$0.0100 (−0.29%) on the dayAs of the close; data may be delayed.
LXEO price, last 12 months
Key stats
- Previous close
- $3.39
- Open
- $3.40
- Day range
- $3.27 – $3.46
- 52-week range
- $3.27 – $10.99
- Volume
- 831.5K
- Avg volume (20 days)
- 1M
- Market cap
- $271.7M
Performance
1W−19.5%
1M−32.5%
3M−28.8%
6M−40.2%
YTD−66.0%
1Y−48.3%
vs S&P 500, 1Y−65.1 pts
Technicals and fundamentals
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $271.7M